CN103110743B - 一种治疗或预防神经衰弱的中药组合物及其制备方法 - Google Patents
一种治疗或预防神经衰弱的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN103110743B CN103110743B CN201310073671.6A CN201310073671A CN103110743B CN 103110743 B CN103110743 B CN 103110743B CN 201310073671 A CN201310073671 A CN 201310073671A CN 103110743 B CN103110743 B CN 103110743B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- neurasthenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010003549 asthenia Diseases 0.000 title claims abstract description 21
- 208000007443 Neurasthenia Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 18
- 241000931705 Cicada Species 0.000 claims abstract description 9
- 241001071795 Gentiana Species 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 9
- 241000208966 Polygala Species 0.000 claims description 9
- 241000245240 Lonicera Species 0.000 claims description 8
- 235000014435 Mentha Nutrition 0.000 claims description 8
- 241001072983 Mentha Species 0.000 claims description 8
- 241000207929 Scutellaria Species 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 230000003340 mental effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 240000005482 Albizia procera Species 0.000 claims 1
- 240000008866 Ziziphus nummularia Species 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 3
- 241000146384 Glaux Species 0.000 abstract description 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 230000007958 sleep Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 9
- 241000220433 Albizia Species 0.000 description 8
- 101100188686 Danio rerio opn1sw2 gene Proteins 0.000 description 8
- 102100031414 EF-hand domain-containing protein D1 Human genes 0.000 description 8
- 101150096151 EFHD1 gene Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 101150089053 SWS2 gene Proteins 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 241001247821 Ziziphus Species 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 210000000582 semen Anatomy 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 210000003128 head Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010057315 Daydreaming Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000002279 cholagogic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 230000002557 soporific effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- SRWKSFRBHIWJSD-UHFFFAOYSA-N 6-cyclohexylhexan-1-ol Chemical compound OCCCCCCC1CCCCC1 SRWKSFRBHIWJSD-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 244000141006 Armeniaca sibirica Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001080798 Polygala tenuifolia Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- -1 REMS Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000304447 Sempervivum tectorum Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 238000005255 carburizing Methods 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310073671.6A CN103110743B (zh) | 2013-03-08 | 2013-03-08 | 一种治疗或预防神经衰弱的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310073671.6A CN103110743B (zh) | 2013-03-08 | 2013-03-08 | 一种治疗或预防神经衰弱的中药组合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110743A CN103110743A (zh) | 2013-05-22 |
| CN103110743B true CN103110743B (zh) | 2014-07-23 |
Family
ID=48409147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310073671.6A Active CN103110743B (zh) | 2013-03-08 | 2013-03-08 | 一种治疗或预防神经衰弱的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110743B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012768A (zh) * | 2015-08-21 | 2015-11-04 | 王璐 | 一种治疗神经衰弱的中药 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3251795A (en) * | 1995-05-15 | 1996-11-29 | Yongkang Li | An anti-aids semifluid extract of traditional chinese medici nes and preparation thereof |
| CN1318075C (zh) * | 2005-10-27 | 2007-05-30 | 刘清华 | 一种治疗神经衰弱的汤剂 |
| CN101966290A (zh) * | 2010-09-29 | 2011-02-09 | 申东升 | 一种治疗神经衰弱的药物及其制备方法 |
| CN102188130A (zh) * | 2011-05-04 | 2011-09-21 | 惠州市欧野科技有限公司 | 一种中药与托玛琳混合药丸枕及其制作方法 |
| CN102342992B (zh) * | 2011-10-14 | 2013-04-17 | 孙丰卿 | 一种用于治疗失眠的中药组合物及其制剂的制备方法 |
| CN102836228B (zh) * | 2012-10-10 | 2014-06-25 | 滨州医学院附属医院 | 一种治疗结膜炎的中药组合物及其制备方法和应用 |
-
2013
- 2013-03-08 CN CN201310073671.6A patent/CN103110743B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110743A (zh) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101342317B (zh) | 一种治疗肺结核的药物组合物及其制备方法 | |
| CN103301412A (zh) | 一种治疗酒精肝的中药组合物 | |
| CN103990081A (zh) | 一种中药组合物及其在制备治疗婴幼儿黄疸药物中的用途 | |
| CN102188613B (zh) | 一种治疗糖尿病的中药制剂 | |
| CN101549101B (zh) | 一种用于治疗尘肺病和耐药性肺结核病的中药及制备方法 | |
| CN103263531B (zh) | 一种治疗三叉神经痛的中药组合物及其制备方法 | |
| CN103041256B (zh) | 一种治疗小儿反复呼吸道感染的中药制剂 | |
| CN103169798A (zh) | 治疗梅尼埃病的中药组合物及其制备方法 | |
| CN103041257B (zh) | 治疗小儿发热高烧呼吸道感染的中药制剂 | |
| CN104888131A (zh) | 一种治疗失眠的中药组合物 | |
| CN120053518A (zh) | 一种治疗湿热外感的中药组合物、制剂、制备方法及应用 | |
| CN103041255B (zh) | 治疗小儿咽喉肿痛呼吸道感染的中药制剂 | |
| CN103110743B (zh) | 一种治疗或预防神经衰弱的中药组合物及其制备方法 | |
| CN104056242A (zh) | 一种治疗急性胆囊炎的中药组合物及其制备方法 | |
| CN102579677A (zh) | 一种治疗脑胶质瘤的中药组合物 | |
| CN103041320B (zh) | 一种治疗颈椎病的中药组合物及其制备方法 | |
| CN105796966A (zh) | 防治慢性疲劳综合症的中药组合物及其制备方法和应用 | |
| CN105396039A (zh) | 防治小儿反复感冒的药物组合物及其制备方法 | |
| CN105521332A (zh) | 治疗肛裂的中药组合物及其制备方法和应用 | |
| CN104606600A (zh) | 一种治疗间质性肺病的中药组合物及其制备方法 | |
| CN104083548A (zh) | 一种治疗卵巢囊肿的中药组合物及其制备方法 | |
| CN104523929A (zh) | 一种治疗感冒的中药组合物及其制备方法与应用 | |
| CN103893489A (zh) | 一种治疗睡眠障碍的药物及制备方法 | |
| CN104189769A (zh) | 一种治疗睡眠障碍的中药组合物及其制备方法 | |
| CN103861041A (zh) | 一种治疗急慢性鼻炎的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CUI HEFANG Effective date: 20140915 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140915 Address after: 226200 chemical industry park, Nantong, Jiangsu, Qidong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee before: Cui Hefang |